Hemcheck Sweden AB has filed a new patent application regarding a product system for the blood gas market. This is according to the current strategy to protect the company’s intellectual property. This application is partly based on the development work that has been done since last year regarding a new product for the blood gas market.

Hemcheck cannot release more information about the patent application today. The application will be handled according to current patent application processes. Hemcheck will, as soon as it is possible, release more information to the market.

– It’s very important for Hemcheck to have strong intellectual property protection, so it’s very positive  that we have submitted this patent application, in addition to the ones we already have. The ambition is that this will strengthen our potential to commercialize future products and systems, as well as increasing the value of our immaterial assets, says Joen Averstad, CEO of Hemcheck.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.